Paul from Austria

Registered at the short selling broker Capital, 5 minutes ago.

» Try Capital you too
67.7% of retail investor accounts lose money when trading CFDs with Capital.
Don't show again

Takeda Pharmaceutical Co., Ltd (TAK) shares information

Takeda Pharmaceutical Co – ADR

24h Change

-2.21 %


Live rate: Market closed

Stock data per Thursday 21 Sep, 2023

-0.36 (-2.21%)
US Market is closed

Live Stock price in graph for Takeda Pharmaceutical Co – ADR (TAK)

  • Latest Volume

    102 (-99.99 %)

  • Volume prev. day


  • Avg. daily volume


  • Market cap


  • P/E ratio


  • Today high

    16.02 USD

  • Today low

    15.92 USD

  • 52 week high

    17.15 USD

  • 52 week low

    12.05 USD

  • YTD Change

    + 1.86 %

Quick links


Latest news about Takeda Pharmaceutical Co – ADR

Below you can find the most recent news posts about Takeda Pharmaceutical Co – ADR, primarily from US and UK based news sources.

Takeda: FDA Accepts NDA Resubmission Of TAK-721 For Short-Term Treatment Of Eosinophilic Esophagitis

Wednesday, 20 September 2023, 15:00:00
TOKYO (dpa-AFX) – Takeda Pharmaceutical Co. Ltd. (TAK) announced Wednesday that the U.S. Food and Drug Administration has accepted for review its New Drug Application or NDA resubmission for TAK-7…
— Finanz Nachrichten

Takeda eosinophilic esophagitis asset resubmission accepted by FDA

Wednesday, 20 September 2023, 14:52:06
The US FDA has accepted resubmission of a New Drug Application for Takeda Pharmaceutical”s (TAK) eosinophilic esophagitis candidate TAK-721. Read more here.
— Seeking Alpha

Is This 250-Year-Old Japanese Big Pharma Giant Selling For Half Price Right Now?

Monday, 18 September 2023, 17:31:30
When it comes to Big Pharma, Japan’s Takeda Pharmaceutical Co Ltd (NYSE: TAK ) is a conservative play that could prove to be a big winner given its cheap valuation and suite of new drugs that portend to dominate in treating niche illnesses. Takeda Pharma is Japan’s largest pharmaceutical company with some innovative products in the pipeline across the cancer, gastro, neuro, rare diseases and plasma therapeutics sectors. These potentially lucrative specializations put it at the forefront of global pharma innovation in what is increasingly looking like a sluggish sector, some say. On September 13, Takeda said that the Food & Drug Administration (FDA) had accepted for review its second ENTYVIO drug application to treat Chron’s Disease following an April acceptance for its first submission. ENTVIO represents a much more user-friendly improvement over the present treatments on the market which are administered intravenously. Two days earlier, Takeda said that it was entering its TAK-249 oral drug for active psoriatic arthritis into Phase 3 trials after it showed a clear 20% percent improvement over the placebo in the Phase 2b trial.
— Benzinga

Japan”s Takeda Pharma commits $30+ M in five new global CSR partnerships

Wednesday, 13 September 2023, 22:53:01
… new partnerships to its Global Corporate Social Responsibility (CSR ) Programme, which contribute to strengthening … partnerships. Takeda expects that Global CSR Programme’s new five partnerships …
— EIN News Corporate Social Responsibility

Takeda Says FDA Accepts BLA For ENTYVIO For Maintenance Therapy In Crohn”s Disease

Wednesday, 13 September 2023, 14:37:41
Takeda Pharmaceutical Co. Ltd. (TAK) announced Wednesday that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for the investigational subcutaneous (SC) administration of ENTYVIO (vedolizumab) for maintenance therapy in adults with moderately to severely active Crohn”s disease (CD) after induction therapy with ENTYVIO intravenous (IV).
— RTT News

Trading broker recommendation

We recommend that you check out as they have a very good selection of stocks available for both going short and long.

Rating: 9.57/10
Minimum deposit: €250 by bank
Description: offer a large number of stocks for trading. Register an account today and check if they have TAK available or trade one of the many other CFD stocks they have.
Risk warning: 67.7% of retail investor accounts lose money when trading CFDs with Capital.